Discussion and Conclusion
Median overall survival for recurrent ovarian cancer is reported to be
46 months[15] .Here, we present a rare
case of recurrent ovarian cancer with a survival period of 122 months.
The treatment with antitumor Chinese medicine injection as maintenance
therapy surprisingly resulted in a durable tumor control. In addition,
no adverse reactions or tumor recurrence have been reported. Antitumor
Chinese medicine injection has been widely used as a combination therapy
for ovarian cancer in China to improve clinical efficacy, reduce side
effects of chemotherapy and improve patients ’quality of
life[16] .A recent study showed that
matrine in ovarian cancer mainly through the regulation of ERK/JNK,
PI3K/AKT, NF-κB pathway to play its anti-proliferation, pro-apoptosis
mechanism to achieve anti-tumor
purposes[17] .Another study showed that
Aidi injection can reduce the expression levels of CEA, CA153 and HE4 in
ovarian cancer markers in rats, regulate PI3K/mTOR signaling pathway to
inhibit ovarian cancer cell proliferation and induce
apoptosis[18] .
This patient was diagnosed with high-grade serous ovarian cancer.
Approximately 70% of epithelial ovarian cancer recurred within 1-2
years of diagnosis[19] .In this case, Aidi
combined with Kushen provides a safe and effective method, and we
believe that these two traditional Chinese medicine injections may
participate in antitumor therapy. Although the exact mechanism of Aidi
combined with Kushen in preventing recurrence and metastasis of ovarian
cancer is not fully understood, it has demonstrated satisfactory
clinical effects and no significant adverse reactions. However, Further
studies are needed to determine the safety and efficacy of Aidi combined
with compound Sophora flavescens as a viable treatment regimen for
ovarian cancer recurrence and metastasis.